Phenomenex Expands Strata™-X SPE Line to Extract Neutral Drugs of Abuse in Forensic Toxicology

Torrance, CA (August 25, 2011) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces Strata-X-Drug N, its second solid phase extraction (SPE) sorbent specially designed for the extraction of drugs of abuse in forensic toxicology. The new sorbent targets neutral drugs such as barbiturates and benzodiazepines. Like its counterpart for basic drug of abuse testing, Strata-X-Drug B, the new sorbent saves time and reduces solvent expense because it does not require conditioning or equilibration.

Phenomenex conducts stringent QC tests on Strata-X-Drug N products; each batch is tested by extracting lorazepam and temazepam from actual urine samples, which delivers more realistic results than testing from spiked water. Samples prepared using Strata-X-Drug N are ready for LC or GC analysis, and methods are available using Phenomenex Kinetex® (LC) and Zebron® (GC) columns.

“Our QC processes use biological samples to ensure the sorbent will perform as expected in customer analyses,” explained Erica Pike, brand manager for Phenomenex. “User satisfaction and consumer adoption has been very high with Strata-X-Drug B, so we have no doubt that Strata-X-Drug N will follow suit.”

Strata-X-Drug N is offered in 1, 3, 6 and 12 mL SPE tubes and in 96-well plates. Additional information featuring the Strata-X-Drug SPE product family can be accessed at: http://www.phenomenex.com/info/page/spedoa.

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical, government and academic laboratories. From drug discovery and pharmaceutical development to disease diagnosis, food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com.

Contacts:
Jennifer Dahlgren, Dahlgren Communications
Phone: (530) 265-0538    
E-mail: [email protected]

Erica Pike, Phenomenex, Inc.
Phone: (310) 212-0555 Ext. 3301
E-mail: [email protected]